Welgene Biotech (6661) reported revenue of NT$33.9 million for Oct 2026, +22.2% year on year and -4.5% from the previous month. Revenue for Jan–Oct 2026 was NT$325.9 million (+6.5% year on year).
In Oct 2026, it ranked No. 114 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$33.9 million | +22.2% | -4.5% |
| Sep 2026 | NT$35.5 million | +19.6% | +10.2% |
| Aug 2026 | NT$32.3 million | -31.2% | -2.7% |
| Jul 2026 | NT$33.2 million | -0.9% | -0.3% |
| Jun 2026 | NT$33.3 million | +0.1% | -22.9% |
| May 2026 | NT$43.1 million | +33.4% | +40.0% |
| Apr 2026 | NT$30.8 million | +25.5% | +7.1% |
| Mar 2026 | NT$28.8 million | +0.9% | +10.7% |
| Feb 2026 | NT$26 million | -2.9% | -10.5% |
| Jan 2026 | NT$29 million | +28.2% | -19.3% |
| Dec 2025 | NT$36 million | +8.2% | +5.4% |
| Nov 2025 | NT$34.1 million | +15.6% | +22.9% |
| Oct 2025 | NT$27.8 million | +11.5% | -6.6% |
| Sep 2025 | NT$29.7 million | +28.9% | -36.7% |
| Aug 2025 | NT$46.9 million | +94.0% | +40.3% |
| Jul 2025 | NT$33.4 million | -22.6% | +0.6% |
| Jun 2025 | NT$33.2 million | +43.7% | +2.8% |
| May 2025 | NT$32.3 million | -2.9% | +31.8% |
| Apr 2025 | NT$24.5 million | +25.3% | -13.9% |
| Mar 2025 | NT$28.5 million | +28.3% | +6.5% |
| Feb 2025 | NT$26.8 million | +32.6% | +18.3% |
| Jan 2025 | NT$22.6 million | -13.0% | -31.9% |
| Dec 2024 | NT$33.2 million | +24.1% | +12.6% |
| Nov 2024 | NT$29.5 million | +17.1% | +18.5% |
| Oct 2024 | NT$24.9 million | +15.0% | +8.0% |
Jan–Oct 2026 cumulative: NT$325.9 million (+6.5% YoY)
Other Biotech & Medical companies
Compare with peers: Welgene Biotech vs PEC / Welgene Biotech vs Lotus Pharm / Welgene Biotech vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16